Prime Medicine ($PRME) Stock Forecast: Up 8.9% Today

What is Prime Medicine?

Prime Medicine (PRME.US) is a biotechnology company focused on developing innovative therapies for genetic disorders. Today, the stock had a strong bullish movement in the market.

Why is Prime Medicine going up?

PRME stock is up 8.9% on Jun 26, 2026 14:00

• A financial firm maintains a Buy rating for Prime Medicine and sets a target price of $6, indicating confidence in the company's growth prospects.
• The FDA granting Regenerative Medicine Advanced Therapy (RMAT) designation to PM359, Prime Medicine's investigational therapy for chronic granulomatous disease (CGD), has likely boosted investor optimism.
• The RMAT designation expedites the development and review process for PM359, highlighting the potential for accelerated market entry and revenue generation.
• Positive Phase 1/2 clinical data and multiple fast-track designations emphasize the promising outlook for PM359 and Prime Medicine, driving investor interest and contributing to the bullish market movement.

PRME Price Chart

PRME Technical Analysis

PRME News

LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6

LifeSci Capital has reiterated its Buy rating for Prime Medicine (PRME.US) and maintained a target price of $6. The firm's analysis supports a positive outlook for the company.

https://www.moomoo.com/news/post/71891910/lifesci-capital-maintains-prime-medicine-prmeus-with-buy-rating-maintains

Prime Medicine Says PM359 Granted US FDA Regenerative Medicine Advanced Therapy Designation

Prime Medicine announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359. PM359 is an investigational Prime Editor designed to correct the genetic cause of chronic granulomatous disease (CGD). The company previously received Orphan Drug Designation from the FDA and the European Medicines Agency (EMA) for PM359 for CGD.

https://www.moomoo.com/news/post/71829787/prime-medicine-says-pm359-granted-us-fda-regenerative-medicine-advanced

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Prime Medicine, Inc. announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359 for the treatment of p47 phox -deficient chronic granulomatous disease (CGD). This designation is based on promising Phase 1/2 clinical data, including results published in The New England Journal of Medicine, which indicate PM359's potential to address the significant unmet medical needs of CGD patients. The RMAT designation will facilitate expedited development and review, adding to existing Fast Track, Orphan Drug, and Rare Pediatric Disease Designations for PM359.

https://www.globenewswire.com/news-release/2026/06/22/3315247/0/en/Prime-Medicine-Receives-U-S-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-PM359-for-the-Treatment-of-Chronic-Granulomatous-Disease-CGD.html

Prime Medicine’s CGD therapy gets FDA RMAT, speeding review

Prime Medicine (PRME) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its investigational therapy PM359, aimed at treating p47phox-deficient chronic granulomatous disease (CGD). This designation, supported by positive Phase 1/2 clinical data, expedites the development and review process, allowing for intensive FDA interaction and eligibility for rolling and priority Biologics License Application review. PM359 now holds multiple fast-track designations, underscoring the urgent need for effective treatments for this serious genetic disorder.

https://www.stocktitan.net/news/PRME/prime-medicine-receives-u-s-fda-regenerative-medicine-advanced-49g2uj0ysq0y.html

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Prime Medicine, Inc. announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359 for the treatment of p47 phox-deficient chronic granulomatous disease (CGD). This designation is based on promising Phase 1/2 clinical data, including results published in The New England Journal of Medicine, which showed PM359's potential to provide a one-time, disease-modifying treatment. The RMAT designation will facilitate expedited development and review, adding to existing Fast Track, Orphan Drug, and Rare Pediatric Disease Designations for PM359.

https://www.globenewswire.com/news-release/2026/06/22/3315247/0/en/prime-medicine-receives-u-s-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-pm359-for-the-treatment-of-chronic-granulomatous-disease-cgd.html

Trending Today

McCormick & Company Incorporated ($MKC) Stock Forecast: Up 5.5% Today

Stryker Corporation ($SYK) Stock Forecast: Up 5.4% Today

Salesforce.com Inc ($CRM) Stock Forecast: Up 5.3% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 6.7% Today

Cisco Systems Inc. ($CSCO) Stock Forecast: Down 5.0% Today

Fastly Inc. ($FSLY) Stock Forecast: Up 6.0% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 5.9% Today

Shopify Inc. Class A Subordinate ($SHOP) Stock Forecast: Up 5.4% Today

Caterpillar Inc. ($CAT) Stock Forecast: Down 5.1% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 5.3% Today

Prime Medicine Price History

16.05.2026 - PRME Stock was down 5.9%

• Prime Medicine reported a large net loss due to heavy R&D investment in its Prime Editing platform, which might have concerned investors and led to a bearish movement in the stock.
• The revenue growth in fiscal 2025 was overshadowed by the significant net loss, indicating that investors are cautious about the company's profitability in the near term.
• The presentation at the Goldman Sachs conference did not seem to have a positive impact on the stock, as the market might be waiting for concrete results or financial stability before reacting positively to the company's initiatives.

29.04.2026 - PRME Stock was up 6.5%

• Presence at the Jefferies Global Healthcare Conference probably boosted investor confidence in Prime Medicine's cutting-edge gene editing therapies.
• Concentration on creating curative genetic treatments for a range of medical fields might have garnered favorable interest from investors.
• The company's dedication to accurately fixing genetic mutations could have established it as a frontrunner in the biotechnology industry, fueling positive sentiment and stock price increase.

14.04.2026 - PRME Stock was down 5.1%

• PRME's Q1 report showed a loss and revenue below estimates, causing a downward market trend.
• The EPS of (28c) compared to the anticipated (25c) may have disappointed investors, influencing the bearish movement.
• While revenue exceeded predictions, the overall financial performance falling short of analysts' expectations could have triggered negativity among investors.
• H.C. Wainwright's hold rating and the projection of declining earnings along with significant revenue growth could have increased uncertainty, impacting PRME's stock price adversely.

08.04.2026 - PRME Stock was down 0.2%

• Today's decline in PRME stock could be attributed to various factors:
• The Q1 2026 net loss exceeding expectations might have sparked worries among investors regarding the company's financial stability and operational longevity.
• Despite positive regulatory filings and anticipated clinical data progress in its pipeline programs, the market could have been underwhelmed by the absence of significant revenue-generating milestones in the immediate future.
• While the hiring of a new CFO could be seen as a positive move for the company's leadership, it might have introduced an element of uncertainty affecting investor sentiment.
• Overall, today's market sentiment towards PRME appears to have been swayed more by immediate financial performance concerns rather than the future promise of its gene-editing technologies.

17.05.2026 - PRME Stock was up 6.9%

• PRME stock experienced a strong bullish movement likely due to positive analyst earnings forecasts and a majority "Buy" rating.
• The company's revenue growth in fiscal 2025 despite a net loss could have instilled confidence in investors about its long-term potential.
• Participation in prestigious events like the Goldman Sachs 47th Annual Global Healthcare Conference may have also contributed to the positive market sentiment surrounding PRME.
• Overall, the bullish movement could be attributed to a combination of favorable earnings forecasts, revenue growth, and industry recognition.

07.04.2026 - PRME Stock was down 5.5%

• A rating shift from "strong sell" to "sell" by a prominent financial organization likely influenced the downward movement of PRME stock.
• Disclosures made to the SEC possibly unveiled worrisome details or future prospects, prompting a negative reaction from investors and subsequent stock depreciation.
• Despite significant institutional ownership and its cutting-edge Prime Editing technology, a change in market sentiment due to recent events has led to today's bearish trend for PRME.

07.04.2026 - PRME Stock was down 9.6%

• The bearish movement in PRME stock today could be attributed to several factors:
• Despite reporting a narrower net loss and a cash runway into 2027, investors might have been disappointed by the lack of significant revenue generation in the recent financial results.
• The downgrade of PRME from a "strong sell" to a "sell" rating by an industry analyst could have influenced market sentiment negatively, leading to increased selling pressure on the stock.
• The focus on regulatory filings for PM577 and PM647 in 2026, with clinical data expected in 2027, might have raised concerns among investors about the timeline and success of these programs, leading to a cautious approach towards the stock.
• The overall market sentiment towards biotechnology companies or the healthcare sector as a whole might have been bearish today, impacting PRME along with other similar stocks in the industry.

26.05.2026 - PRME Stock was up 8.9%

• A financial firm maintains a Buy rating for Prime Medicine and sets a target price of $6, indicating confidence in the company's growth prospects.
• The FDA granting Regenerative Medicine Advanced Therapy (RMAT) designation to PM359, Prime Medicine's investigational therapy for chronic granulomatous disease (CGD), has likely boosted investor optimism.
• The RMAT designation expedites the development and review process for PM359, highlighting the potential for accelerated market entry and revenue generation.
• Positive Phase 1/2 clinical data and multiple fast-track designations emphasize the promising outlook for PM359 and Prime Medicine, driving investor interest and contributing to the bullish market movement.

04.05.2026 - PRME Stock was up 11.9%

• The bullish movement in PRME stock today could be attributed to the positive market sentiment generated by the announcement of the CEO's participation in the prestigious Goldman Sachs 47th Annual Global Healthcare Conference.
• Investors may view Prime Medicine's focus on developing innovative genetic therapies and its potential to repair a wide range of genetic mutations as a promising opportunity for growth and advancement in the biotechnology sector.
• The live audio webcast of the presentation may have increased investor confidence in the company's future prospects, leading to increased buying activity and driving the stock price higher.

09.05.2026 - PRME Stock was down 5.1%

• Concerns have arisen among investors due to the issuance of 75,000 stock options to multiple directors at Prime Medicine, possibly impacting the stock price by diluting existing shares.
• The stock options grant may be viewed by investors as a lack of short-term confidence in the company, which could be contributing to the current bearish movement.
• The rise in derivative securities holdings by directors might indicate a misalignment between management and shareholders, resulting in diminished investor confidence and a decrease in the stock's value.

11.04.2026 - PRME Stock was up 5.9%

• Despite reporting a Q1 loss and missing revenue estimates, Prime Medicine (PRME) experienced a bullish market movement today.
• The bullish trend could be attributed to the company's strategic initiatives, such as appointing new executives, initiating equity offerings, and prioritizing its liver disease programs.
• Analysts forecasting significant revenue growth and a higher price target for PRME might have also contributed to the positive market sentiment.
• Investors seem optimistic about Prime Medicine's gene-editing pipeline progress, promising preclinical data, and ongoing regulatory efforts, leading to the bullish movement in the stock.

24.05.2026 - PRME Stock was down 5.5%

• The bearish movement in PRME's stock could be attributed to profit-taking by investors after a series of positive news and designations from the FDA regarding their investigational therapy PM359 for chronic granulomatous disease (CGD).
• Despite the positive developments, the market may have reacted negatively due to potential concerns about the company's ability to successfully bring PM359 to market and generate significant revenue.
• Analysts' bullish sentiment on PRME prior to the bearish movement indicates that there was optimism surrounding the company, but short-term market fluctuations and profit-taking could have overshadowed this positive outlook.
• Overall, the bearish movement in PRME's stock today may be a temporary setback amidst a broader positive outlook for the company's innovative therapies in the healthcare sector.